Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Assessing potential of psilocybin for depressive disorders

Kozak, Zofia, Johnson, Matthew W., Aaronson, Scott T. · 2023 · Expert Opinion on Investigational Drugs

Abstract

INTRODUCTION: There has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression. AREASCOVERED: We discuss the current understanding of psilocybin's therapeutic mechanism of action and review existing clinical data investigating psilocybin as a novel therapeutic agent for the treatment of depression. EXPERT OPINION: There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2023.2273493

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 74 references

Research works printed but not linked: 2

  1. Agrawal M Emanuel E Richards B et al. Assessment of psilocybin therapy for patients with cancer and major depression disorder. JAMA Oncol [Internet]. 2023 [cited 2023 Jun 5]; Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2803623.
  2. Paglia C. Cults and cosmic consciousness: religious vision in the American. Arion. 2003;10(3): 1–111.

Cited by

See all 11

Metadata

Authors
Kozak, Z., Johnson, M. W., & Aaronson, S. T.
Affiliations
  • University of Maryland, Baltimore (US)
  • Johns Hopkins University (US)
Corresponding author
Aaronson, Scott T.
Venue
Expert Opinion on Investigational Drugs
Published
2023-10-03
Volume
32
Issue
10
Pages
887-900
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W4387866078
Cited by
11
References
74
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 1
FWCI
0.56
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
psilocybin, depression, treatment-resistant depression, psychedelic therapy, clinical trials, benefits and risks, antidepressant efficacy
MeSH terms
Hallucinogens, Humans, Psilocybin, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessing potential of psilocybin for depressive disorders. https://app.cochat.ai/papers/10.1080/13543784.2023.2273493
The paper
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023). Assessing potential of psilocybin for depressive disorders. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2023.2273493

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.